NCT06880042View on ClinicalTrials.gov

COMPARISON OF EFFICACY AND SAFETY OF NARROWBAND UVB WITH 0.1% TACROLIMUS VS NARROWBAND UVB WITH 0.005% CALCIPOTRIOL IN TREATMENT OF VITILIGO

EARLY_PHASE1Enrolling by invitationINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

May 1, 2025

Primary Completion Date

June 30, 2025

Study Completion Date

August 30, 2025

Conditions
Vitiligo - Macular DepigmentationTacrolimus
Interventions
DRUG

Tacrolimus

Tacrolimus is calcineurin inhibitor that will act as immunomodulator

DRUG

Calcipotriol

Calcipotriol is a vitamin D analogue that will act as immunomodulator

Trial Locations (1)

Unknown

Lahore general.hospital, Lahore

All Listed Sponsors
lead

Dr ayesha wahid

OTHER_GOV